This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AG-858
Description: AG-858 is a personalized cancer vaccine based on Antigenics’ proprietary heat shock protein technology. Derived from each patient’s cancerous cells, the vaccine consists of the heat shock protein HSP70 and its associated peptides. It is designed to capture the ‘antigenic fingerprint’ of the patient’s particular cancer to reprogram the body’s immune system to target and destroy only the cells bearing this fingerprint.
Additional information available to subscribers only: